Liedberg Fredrik, Hagberg Oskar, Holmäng Sten, Hosseini Aliabad Abolfazl, Jancke Georg, Ljungberg Börje, Malmström Per-Uno, Åberg Hanna, Jahnson Staffan
Department of Urology, Skåne University Hospital, Lund-Malmö , Malmö , Sweden.
Scand J Urol. 2015;49(4):290-5. doi: 10.3109/21681805.2014.1000963. Epub 2015 Jan 26.
The aim of this study was to investigate recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) in a large population-based setting.
Patients with bladder cancer (stage Ta, T1 or carcinoma in situ) diagnosed in 2004-2007 (n = 5839) in Sweden were investigated 5 years after diagnosis using a questionnaire. Differences in time to recurrence and progression were analysed in relation to age, gender, tumour stage and grade, intravesical treatment, healthcare region, and hospital volume of NMIBC patients (stratified in three equally large groups).
Local bladder recurrence and progression occurred in 50 and 9% of the patients, respectively. The rate of local recurrence was 56% in the southern healthcare region compared to 37% in the northern region. A multivariate Cox proportional hazards model, adjusting for age, gender, tumour stage and grade, intravesical treatment, healthcare region and hospital volume, showed that recurrence was associated with TaG2 and T1 disease, no intravesical treatment and treatment in the southern healthcare region, but indicated a lower risk of recurrence in the northern healthcare region. Adjusting for the same factors in a multivariate analysis suggested that increased relative risk of progression correlated with older age, higher tumour stage and grade, and diagnosis in the Uppsala/Örebro healthcare region, whereas such risk was decreased by intravesical treatment (relative risk 0.72, 95% confidence interval 0.55-0.93, p = 0.012).
The incidence of NMIBC recurrence and progression was found to be high in Sweden, and important disparities in outcome related to care patterns appear to exist between different healthcare regions.
本研究旨在调查在基于人群的大样本中,非肌层浸润性膀胱癌(NMIBC)的复发和进展情况。
对2004年至2007年在瑞典诊断为膀胱癌(Ta期、T1期或原位癌)的患者(n = 5839)在诊断5年后进行问卷调查。分析NMIBC患者(分为三个同等规模的组)复发和进展时间的差异与年龄、性别、肿瘤分期和分级、膀胱内治疗、医疗保健区域以及医院规模的关系。
分别有50%和9%的患者出现局部膀胱复发和进展。南部医疗保健区域的局部复发率为56%,而北部区域为37%。多变量Cox比例风险模型在对年龄、性别、肿瘤分期和分级、膀胱内治疗、医疗保健区域和医院规模进行校正后显示,复发与TaG2和T1期疾病、未进行膀胱内治疗以及在南部医疗保健区域接受治疗有关,但提示北部医疗保健区域的复发风险较低。多变量分析中对相同因素进行校正表明,进展的相对风险增加与年龄较大、肿瘤分期和分级较高以及在乌普萨拉/厄勒布鲁医疗保健区域的诊断有关,而膀胱内治疗可降低这种风险(相对风险0.72,95%置信区间0.55 - 0.93,p = 0.012)。
在瑞典,NMIBC复发和进展的发生率较高,不同医疗保健区域之间在与护理模式相关的结局方面似乎存在重要差异。